Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

Rahimi H., Salehiabar M., Charmi J., BARSBAY M., Ghaffarlou M., Razligh M. R., ...Daha Fazla

NANO TODAY, cilt.34, 2020 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 34
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.nantod.2020.100895
  • Dergi Adı: NANO TODAY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Compendex, EMBASE, INSPEC
  • Anahtar Kelimeler: CRISPR/Cas9, Nanoparticles, Delivery, Genome editing, Non-viral vector, ADENOASSOCIATED VIRUS AAV, MESSENGER-RNA DELIVERY, GENE DELIVERY, IMMUNE-SYSTEM, IN-VITRO, POLYMERIC NANOPARTICLES, MAGNETIC NANOPARTICLES, CAS9 RIBONUCLEOPROTEIN, LIPID NANOPARTICLES, CRISPR-CAS9 SYSTEM
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Exploiting bacterial DNA-acting enzymes and expanding their repertoire for genome engineering have been major technological and conceptual advances in molecular biology over the last decade. The CRISPR-Cas9 system offers many attractive superiorities, such as multiplexing, high precision, low cost, and simplicity compared to other strategies/systems/approaches known to date for gene editing. The efficient co-delivery of Cas9 and single guide RNA(s) into a desired cell and subsequent correct targeting of selected genomic fragment(s) are among the most critical and determining issues for CRISPR-Cas9-based genome engineering. CRISPR/Cas9 components can be transported into target cells via various delivery methods, including physical methods (such as electroporation and microinjection) as well as viral and non-viral methods. Physical and viral methods, with all their privileges, still suffer from disadvantages including induction of immune responses, cell damage, lack of high specificity, etc. We are witnessing a remarkable increase in the employment of nanomaterials as non-viral carriers for the delivery of the CRISPR/Cas9 system. Nanoparticles have so far presented numerous advantages such as ease of synthesis, high efficiency, low cost, size tunability, non-mutagenicity, non-immunogenicity, etc. with regard to the delivery of CRISPR/Cas9. Here, we will review the recent progress in the delivery of CRISPR/Cas9 system components via nanomaterials and outline future challenges. (C) 2020 Elsevier Ltd. All rights reserved.